Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04200365
Other study ID # BMT29
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date June 5, 2020
Est. completion date September 7, 2023

Study information

Verified date November 2023
Source SCRI Development Innovations, LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is being done in patients who have been receiving corticosteroids or other immunosuppressive therapies for the treatment of cGVHD for at least 6 months. The purpose of this study is to find out if itacitinib in combination with corticosteroids or other immunosuppressive therapies is safe and effective in people with cGVHD.


Description:

Graft versus host disease remains a major hurdle to improve allogeneic hematopoietic stem cell transplantation outcome, with cGVHD being associated with decreased quality of life. Suppression of the immune system with corticosteroids forms the basis of first-line therapy for management of GVHD, but sustained responses are usually seen in less than 50 percent of patients and there is no standard second- or third-line treatment for steroid refractory cGVHD. Identification of novel therapeutic targets are needed to improve outcomes. Therapeutic potential has been shown by a JAK inhibitor in the treatment of steroid refractory GVHD. Itacitinib is a novel, selective inhibitor of the JAK family of protein tyrosine kinases and will be studied here in patients with steroid refractory cGVHD.


Recruitment information / eligibility

Status Terminated
Enrollment 15
Est. completion date September 7, 2023
Est. primary completion date September 7, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Written informed consent signed by the patient or legal guardian prior to any study-related screening procedures 2. Patients who have undergone allo-hematopoietic stem cell transplant(s) (HSCT) from any donor HLA type (related or unrelated donor with any degree of HLA matching) using any graft source (bone marrow, peripheral blood stem cells, or cord blood). Recipients of non-myeloablative, myeloablative, and reduced intensity conditions are eligible. 3. Active, clinically diagnosed, moderate or severe cGVHD per NIH Consensus Criteria: - Moderate cGVHD: at least 1 organ (except lung) with a score of 2, =3 organs involved with a score of 1 in each organ, or lung score of 1 - Severe cGVHD: at least 1 organ with a score of 3, or lung score of 2 or 3 4. cGVHD must be refractory to steroids defined by at least one criteria: - Patient is refractory to glucocorticoid therapy at screening: ongoing treatment with prednisone equivalent =0.20 mg/kg/day x 4 weeks (wks) at screening and organ progression documented 4 wks after the initiation of this regimen - Patient is dependent on glucocorticoid therapy at screening: treatment with a prednisone equivalent mean dose =0.20 mg/kg/day received for 12 wks at screening - Patient is intolerant to glucocorticoids at screening: ongoing treatment with prednisone equivalent =0.20 mg/kg/day x 4 wks at screening and presence of at least one documented glucocorticoid toxicity 5. Evidence of myeloid and platelet engraftment (absolute neutrophil count ?1,000/mm^3 and platelet count ?25,000/mm^3). Use of growth factors or platelet transfusions is not allowed within 7 days before screening of laboratory assessment. 6. Patients must currently be receiving systemic or other immunosuppressive therapies for the treatment of cGVHD for a duration of ?6 months prior to start of study treatment 7. Patients must be able to swallow and retain oral medication 8. Eastern Cooperative Oncology Group Performance Status score of 0, 1, or 2 9. Adequate hematologic function 10. Adequate renal function: creatinine clearance =30 mL/min measured or calculated by Cockcroft Gault equation 11. Patients willing to avoid pregnancy or father children based on 1 of the following: - Women of non-childbearing potential (i.e., surgically sterile by hysterectomy and/or bilateral oophorectomy OR =12 months of amenorrhea) - Women of childbearing potential who have a negative serum pregnancy test at screening and who agree to take appropriate precautions to avoid pregnancy from screening through safety follow-up. - Men who agree to take appropriate precautions to avoid fathering children from screening through safety follow-up. Male patients must also refrain from donating sperm during their participation in the study and for at least 3 months after completing the study. 12. Ability to understand the nature of this study and to comply with study and follow-up procedures Exclusion Criteria: 1. Receiving concomitant JAK inhibitor for cGVHD; prior treatment with a JAK inhibitor for acute GVHD is permitted if treatment was stopped more than 60 days prior to study start. Patients are eligible if JAK inhibitors for treatment of cGVHD are stopped due to side effects and not due to refractoriness. 2. Treatment with any other investigational agent, device, or procedure, within 28 days (or 5 half-lives, whichever is longer) of enrollment. For previous study drugs where 5 half-lives is =28 days, a minimum of 10 days between termination of that study drug and administration of itacitinib is required. 3. Presence of current secondary malignancies with the exception of previously treated in situ carcinoma, cervical carcinoma Stage 1B or less, and noninvasive basal cell or squamous cell skin carcinoma. 4. Pregnant or nursing (lactating) women 5. Patients with relapsed primary malignancy, or who have been treated for relapse after the allo-HSCT was performed 6. History of progressive multifocal leukoencephalopathy 7. Evidence of the following infections: - Active uncontrolled bacterial, fungal, parasitic, or viral infection. Infections are considered controlled if appropriate therapy has been instituted and, at the time of screening, no signs of infection progression are present. Progression of infection is defined as hemodynamic instability attributable to sepsis, new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection. - Known HIV infection - Active tuberculosis infection that developed after allo-HSCT - Active viral infection confirmed by polymerase chain reaction for the BK virus ( a polyoma virus), cytomegalovirus, Epstein-Barr virus, and human herpes virus 6 - Active hepatitis B virus (HBV) or hepatitis C virus that requires treatment, or at risk for HBV reactivation (i.e., positive HBsAg) 8. Severe organ dysfunction unrelated to underlying GVHD including: - Cholestatic disorders or unresolved veno-occlusive disease of the liver (persistent bilirubin abnormalities not attributable to GVHD and ongoing organ dysfunction) - Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral itacitinib (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowl resection) - Clinically significant or uncontrolled cardiac disease, including unstable angina, acute myocardial infarction within 6 months of enrollment, New York Heart Association Class III or IV congestive heart failure, circulatory collapse requiring vasopressor or inotropic support, or arrhythmia that requires therapy - Significant respiratory disease that requires mechanical ventilation support or a resting O2 saturation ?90 percent by pulse oximetry or FEV1 ?30 percent 9. Patients requiring platelet transfusions to maintain a platelet count ?25,000/mm^3 10. Any corticosteroid therapy for indications other than cGVHD at doses ?1 mg/kg/day methylprednisone or equivalent within 7 days of study start 11. Patients receiving treatment with medications that interfere with coagulation or platelet function including, but not limited to, aspirin dose exceeding 81 mg/day and related drugs such as heparin or warfarin sodium. Use of low molecular weight heparin is allowed. 12. Known allergies, hypersensitivity, or intolerance to itacitinib or any of its excipients 13. Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Itacitinib
Itacitinib will be administered orally once daily for up to 24 months.

Locations

Country Name City State
United States South Austin Medical Center Austin Texas
United States Texas Oncology - Sammons Cancer Center Dallas Texas
United States Colorado Blood Cancer Institute Denver Colorado
United States The Sarah Cannon Research Institute Nashville Tennessee
United States Texas Transplant Institute San Antonio Texas

Sponsors (2)

Lead Sponsor Collaborator
SCRI Development Innovations, LLC Incyte Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall response rate (ORR) Defined as the proportion of patients with a cGVHD response of complete response (CR) or partial response (PR) after 6 months of treatment as defined by National Institutes of Health Consensus Criteria Approximately 6 months after the beginning of study drug treatment
Secondary Number of patients that can withdraw or decrease steroids Ability to withdraw or decrease steroids to ?0.5 mg/kg of methylprednisolone or equivalent Steroid dose will be assessed prior to first dose of study treatment, throughout study treatment, and when study treatment ends (approximately 2 years)
Secondary Overall survival Defined as the time from the first day of study drug administration to death on study Survival will be assessed every 3 months for 1 year after last dose of study treatment
Secondary Assessment of safety based on frequency of adverse events Safety will be assessed in terms of adverse events Safety will be assessed throughout study treatment until 30 days after the last dose of study treatment (approximately 2 years)
Secondary Quality of life impact Changes in symptom burden will be measured using the Lee Symptom Scale. Subscale scores and the summary score range from 0 to 100, with a higher score indicating worse symptoms. Quality of life will be assessed prior to the start of study treatment, at two timepoints while receiving study treatment, and when study treatment ends (approximately 2 years)
Secondary Number of patients with recurrence or progression of cGVHD Patients will be assessed for severity of cGVHD using clinician- and patient-reported activity assessments and review of steroid dose cGVHD status will be assessed prior to the start of study treatment, throughout study treatment, and when study treatment ends (approximately 2 years)
Secondary Relapse rate of underlying malignancy Patients will be closely monitored for any evidence of underlying disease relapse or recurrence; Formal re-staging will be done at physician discretion Relapse of underlying malignancy will be assessed throughout study treatment, when study treatment ends, and every 3 months for 1 year after last dose of study treatment (approximately 3 years)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04189432 - Efficacy and Safety of SCM-CGH in Patients With Steroid-Refractory or Dependent Chronic Graft-Versus-Host Disease Phase 2
Terminated NCT03557749 - Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies
Completed NCT05121142 - Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease Phase 1
Recruiting NCT04202835 - ATG Plus PTCy vs ATG for CGVHD Prophylaxis Phase 2
Terminated NCT03640481 - Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy Phase 2
Completed NCT01036958 - Development and Validation of a Symptom Scale for Children With Chronic Graft-versus-Host Disease
Recruiting NCT04372524 - Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PTCTC GVH 1901 Study
Active, not recruiting NCT03604692 - A Phase 1/2 Study to Evaluate SNDX- 6352 in Participants With Active cGVHD Phase 1/Phase 2
Recruiting NCT05355675 - The Association of Microbiota Composition With cGVHD After Allo-HSCT
Active, not recruiting NCT04710576 - A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) Phase 2
Not yet recruiting NCT06263478 - A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease Phase 3
Not yet recruiting NCT06388564 - A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease Phase 2
Terminated NCT02123966 - An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-Disease Phase 2
Recruiting NCT05692713 - Polyomic Biomarker Verification in Adult Chronic Graft-Versus-Host Disease (ABLE3.0/CTTC2201)
Terminated NCT04446182 - Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD Phase 2
Active, not recruiting NCT05305989 - Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213 Phase 2
Active, not recruiting NCT02340676 - A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD Phase 2
Completed NCT04540133 - Dexamethasone Solution and Dexamethasone in Mucolox™ Phase 2
Not yet recruiting NCT03190733 - A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT Phase 4
Active, not recruiting NCT04716075 - Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) Phase 2